HDL, apo B/apo A1 ratio, Diabetes Mellitus and Cardiovascular Disease by Sheriff, Dhastagir Sultan et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 8
HDL, apo B/apo A1 ratio, Diabetes Mellitus and
Cardiovascular Disease
Dhastagir Sultan Sheriff, Sachu P. and Elshaari F.A.
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/56476
1. Introduction
In India, diabetes is not an epidemic anymore but has turned into a pandemic. According to
the International Journal of Diabetes in developing Countries India is labelled as the diabetic
capital of the world. The International Diabetes Federation estimates that the number of
diabetic patients in India more than doubled from 19 million in 1995 to 40.9 million in 2007. It
is projected to increase to 69.9 million by 2025.Type II diabetes and its complications constitute
a major worldwide public health problem. Patients with type II diabetes have 2 - 4 times higher
risk of experiencing cardiovascular disease(CVD) than adults without diabetes (Fox et al. 2004;
Laakso,2001) and their relative risk for CVD is about twice as high(Liu et al. 2005), much of
which may be preventable with appropriate treatment of dyslipidemia.
The elevated CVD risk affecting patients with Type II diabetes may be attributed to a combined
dyslipidemia characterized by elevated triglycerides, elevated triglyceride rich remnant
lipoproteins(TGRLP), elevated apolipoprotein (apo) B and low levels of HDL cholesterol, with
a predominance of small, dense low density lipoprotein(LDL) particles amid relatively normal
LDL Cholesterol levels (Chih-yuan wang et al. 2004).
The association of low plasma levels of high-density lipoprotein (HDL) with states of impaired
glucose metabolism and type 2 diabetes mellitus is well established, but the mechanistic links
remain to be fully elucidated. Recent data suggests that HDL directly influences glucose
metabolism through multiple mechanisms. (Drew et al., 2012).
The association of low plasma levels HDL with states of impaired glucose metabolism and
type 2 diabetes mellitus is well established, but the mechanistic links remain to be fully
elucidated. Recent data suggests that HDL directly influences glucose metabolism through
multiple mechanisms. (Drew et al., 2009)
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2. Materials and methods
Study was done on 109 subjects aged 40-75 years from HIGH-Tech Hospital, Cardiology Unit,
Vinayaka Missions, Salem, India. Subjects were selected by simple random technique from the
group of patients who were referred to the department of cardiology for coronary angiography
and who met the inclusion criteria set out above. From all patients a written informed consent
was obtained All data collected during a regular visit to the hospital included, anthropometric
parameters including weight, height and waist circumference were measured using standard
protocols Also a completed questionnaire regarding their medical history, coronary artery
disease(CAD) and its complications, hypertension, age of onset of diabetes mellitus, chronic
diseases other than CAD and diabetes mellitus, medications, socio-economic factors, dietary
habits as well as the family medical history.
3. Grouping of patients
The patients were sub divided into two groups
1. Group I comprised of 52 coronary artery disease patients without type 2 diabetes(T2D)
mellitus.(CAD WDM)
Figure 1. High density Lipoprotein- Main Functions
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2. Group II comprised 57 coronary artery disease patients with type 2 diabetes melli‐
tus(T2D).( CAD WNDM).
3. Control Subjects comprised of 71 age-matched healthy subjects.
PARAMETERS CONTROL (N=71) CAD WNDM( N=52) CAD WDM( N=57)
Age( Years) 52.42 ±6.7 55.4 ± 5.657 52 ±9.5
BMI (kg/m2) 20.05±0.95 27.82 ± 3.359a 32.05 ± 0.33a,b
SBP (mmHg) 116.14±10.25 140.9 ± 16.97a 147.5 ± 28.28a,b
DBP (mmHg) 77.14±7.8 88.92± 14.14a 95.78 ± 21.21a,b
BMI: Body mass index,, SBP: Systolic blood pressure, DBP: diastolic blood pressure. Data are expressed as (mean ± S.D).All
comparisons by t- test. Statistical analysis was done by Anova (post hoc test : Bonferroni.a: Statistically significant from
control group at p<0.05; b:Statistically significant from CAD patients without type 2 DM at p<0.05..
Table 1. Demographic details of study subjects.
4. Coronary angiography and grading of CAD patients
The coronary angiogram was assessed by two cardiologists who were unaware of the current
study. Selective coronary angiography was performed with Judkins technique in all patients.
The severity of coronary atherosclerosis was estimated by calculating the coronary athero‐
sclerotic score (CAS). Jenkins et al.,1978., based on the number of stenotic coronary artery
segments, the degree of their lumen stenosis. The extend and severity of the CAD was assessed
by assigning points to each lesion as follows: less than 50% stenosis of the luminal diameter
1;50-74% stenosis,2;75-100%, 3.The point for each lesion in coronary arteries including
proximal,medial and distal segments were summed and a cumulative CAS obtained. The
severity of CAD was further classified as one, two, three vessel disease according to the number
of stenotic coronary artery in the three major vessels.Significant CAD was defined as more
than 50% stenosis in at least one coronary artery segment.(Fievet. et al.,1991).(Table.2-given
below)
GRADE I <50% stenosis with single vessel disease .(mild)
GRADE II 50-74% stenosis with double vessel disease.(moderate)
GRADE III 75-100% stenosis with triple vessel disease.(severe).
Table 2. Add caption
Anthropometric measurements like Body Mass Index (BMI), Waist Circumference (WC) and
Blood Pressure(BP) were done by standard procedures.
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5. Measurement of Mean Arterial Pressure (MAP)
MAP = [(2 x diastolic) +systolic] / 3 Diastole counts twice as much as systole because 2/3 of the
cardiac cycle is spent in diastole (Zheng et al 2008)
5.1. Biochemical estimations
Routine biochemical investigations were done using serum and plasma. Serum was used for
the determination of insulin and blood glucose on the same day of sample collection. Remain‐
ing serum and plasma were stored at -200C for analyzing other parameters.
5.2. Determination of Homeostasis Model Assessment (HOMA) — IR
The Homeostasis Model Assessment (HOMA) estimates steady state beta cell function (%B)
and insulin sensitivity (%S), as percentages of a normal reference population. (HOMA-IR) is
used in clinical diabetes research to measure insulin sensitivity. The calculation helps correct
for the effects of fasting hyperglycemia (high blood sugar). (Levy JC et al.,1998.)
HOMA IR = (FBS mmol/L)X(Fasting Insulin µU/ml.)/22.5
5.3. Biochemical studies
Serum samples taken were subjected to estimations of glucose, Glycated hemoglobin, insulin,
lipid profile including apo A 1 and apo B. by standard automated methods
5.4. Result
Study was done on 109 subjects who were selected by simple random technique from the group
of patients referred to the department of cardiology for coronary angiography and who met
the inclusion criteria. Study subjects were 39% control subjects(n=71), 29% coronary artery
disease patients without type 2 DM (CAD WNDM, n=52) and 32 % were coronary artery
disease patients with type 2 DM (CAD WDM, n=57). Among the control subjects 65% were
males and 35% were female. Among the CAD WNDM patients 88% were males and 12% were
female and in CAD WDM 82% were male and 18% were female.The base line characteristics
of study subjects are shown in Table 1. Age of the study subjects were from 40 to 75 years. The
mean age of onset of CAD in the group with type 2 DM was 52 ± 4.5 when compared to 59±
6.4 in CAD WNDM. 79% of CAD WDM subjects and 48% of CAD WNDM subjects were of
the age group 51-60 years. The mean duration of diabetes in CAD WDM was 6.2±2.5. Statisti‐
cally no significant difference in SBP and DBP was observed in CAD WDM when compared
to CAD WNDM. Significant difference in BMI was observed in the CAD WDM subjects when
compared to CAD WNDM and control (with p<0.001).The mean BMI level was 32.05 ± 0.33 in
CAD WDM, 27.82 ± 3.359 in CAD WNDM and 20.05±0.95 in the control group respectively.
The occurrence of CAD was computed in relation to age, BMI, and hypertension. (Table.
3.below)
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Variables CAD WNDM N(%) CAD WDM N(%) P value
Age (years)
40-50 15 ( 29 %) 1 (2% )
0.000151-60 25 ( 48 %) 45(79% )
61-70 12 ( 23%) 11(19 % )
BMI (kg/m2)
18.5-24.9 1(2 %) 6(11 % )
0.000425. - 30 28(54 % ) 12(21 % )
>30 23(44 % ) 39( 68% )
Smoking
Yes 13(25% ) 9(16 % )
0.6807No 39(75 % ) 48(84 % )
Alcoholism
Yes 5(10 % ) 11(19 % )
0.2445No 47(90 % ) 46(81 % )
SBP <140mmofHg>140m of Hg
2(4 % ) 4 (7 %)
0.680750(96 % ) 53 ( 93 %)
BMI: Body mass index, SBP: Systolic blood pressure Statistical analysis was done by Chi square test. Statistically significant
from CAD patients without type 2 DM at p<0.001.
Table 3. Relation of Coronary Artery Disease (CAD) to different variables.
Among the study subjects 2% of CAD WNDM had BMI in the range of 18.5-24.9 kg/m2
compared to 11% in CAD WDM. 54% of CAD WNDM had BMI in the range of 25-30 kg/
m2,when compared to 21% in CAD WDM. Also 44% of CAD WNDM had BMI value >30 kg/
m2when compared to 68% in CAD WDM.
CADsubjects Severity of CAD
Grade I Grade II Grade III
CAD WNDM 24(46%) 15(29%) 13(25%)
CAD WDM 9(16%) 12(21%) 36(63%)
CAD WDM: coronary artery disease with diabetes. CAD WNDM coronary artery disease without diabetes.. Statistical
analysis was done by Chi square test.
Table 4. Severity of CAD among the study subjects.
According to the percentage of stenosis and involvement of coronary vessels, severity of CAD
was assessed and classified as Grade I(mild), Grade II(Moderate) and Grade III(Severe).
Analysis on frequency of distribution has revealed that severity was significantly high in CAD
WDM. (Table : 4) The percentage of patients with severe coronary artery disease-Grade III was
63% in CAD WDM Vs 25 % in CAD WN DM(p<0.001). 21% of CAD WDM patients had Grade
HDL, apo B/apo A1 ratio, Diabetes Mellitus and Cardiovascular Disease
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II (moderate) compared to 29% in CAD WNDM.16% of CAD WDM had Grade I (mild) disease
compared to 46% in CAD WNDM. A significantly high percentage of multivessel atheroscle‐
rosis was observed in CAD WDM when compared to CAD WNDM.
PARAMETERS CONTROL(N=71) CAD WNDM (N=52) CAD WDM (N=57)
FBS ( mg/dL) 85.04±6.20 85.65 ± 5.66 147.05 ± 30.40a,b
PPBS ( mg/dL) 101.81±5.10 109.4± 7.07 403.00 ± 53.70a,b
Insulin (µIU/ml) 8.41±0.33 8.76 ± 5.37 22.93 ± 3.25a,b
HOMA - IR 1.77±0.33 1.80± 0.45 9.70 ± 1.10 a,b
Table 5. Serum Fasting Blood glucose, Insulin and HOMA-IR of study subjects
Data are expressed as (mean ± S.D). Statistical analysis was done by Anova (post hoc test :
Bonferroni) a: Statistically significant from control group at p<0.05; b:Statistically significant
from CAD patients without type 2 DM (p<0.05.).
The mean fasting blood glucose of the normal controls, CAD WNDM and CAD WDM subjects
were 85.04±6.2, 85.65 ± 5.657 and 147.05 ± 30.4 respectively. There was significant (p <0.05)
increase in mean Fasting blood glucose in CAD WDM when compared to CAD WNDM and
control. The mean Post prandial blood glucose of the normal controls, CAD WNDM and CAD
WDM were 101.81±5.1, 109.4± 7.071and 403 ± 53.7 respectively. The mean Post Prandial blood
glucose in CAD WDM was significantly high (p<0.05) when compared to CAD WNDM and
control. The mean insulin level among the three groups were 8.41±0.334, 8.76 ± 5.37 and 22.93
± 3.25 respectively. The CAD WDM patients had significantly high insulin level (p<0.05) when
compared to CAD WNDM and control. The mean HOMA IR of controls, CAD WNDM and
CAD WDM were 1.77±0.33, 1.8± 0.445 and 9.7 ± 1.1 respectively. The CAD WDM patients had
significantly high IR level (p<0.05) when compared to CAD WNDM and control.(Table.5.)
One of the basic factor which was found to be significantly elevated in CAD WDM group when
compared to other two groups was Insulin resistance – which is the underlying defect in >90%
of patients with type 2 diabetes mellitus.
IR SEVERITY OF CAD
Grade I Grade II Grade III
<1.6 30(58%) 18(35%) 4(8%)
>1.6 9(16%) 12(21%) 36(69%)
Table 6. IR and Severity of CAD among the CAD subjects
The median value 1.6 was considered as Cut off values in our study.IR: Insulin resistance.
Statistical analysis was done by Analysis was done by Chi square test. (Gary et al., 1997)
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Analysis on frequency of distribution has revealed that severity was significantly high in CAD
subjects with IR >1.6. (Table 6) The percentage of patients with IR >1.6 and Grade III-coronary
artery disease - was 69%, Grade II coronary artery disease - was 21% and Grade I -coronary
artery disease- was 16% respectively. The percentage of subjects with IR <1.6 and Grade III -
severity- was 8%, Grade II coronary artery disease - was 35% and Grade I -coronary artery
disease- was 30% respectively.
6. Body Mass Index (BMI)
Body mass index (BMI) is a simple index of weight-for-height that is commonly used to classify
overweight and obesity in adults. The WHO defines a BMI greater than or equal to 25 is
overweight and a BMI greater than or equal to 30 is obesity(World Health Organization,2007).
BMI: Body mass index. The subjects were graded into I,II,III based on severity Statistical analysis was done by Chi square
test.
Table 7. BMI and severity of CAD among CAD subjects.
Analysis on frequency of distribution has revealed that severity was significantly high in CAD
subjects with BMI >30kg/m2.The percentage of CAD WDM patients with BMI>30 kg/m2 and
Grade III-coronary artery disease - was 44%, Grade II coronary artery disease - was 18% and
Grade I -coronary artery disease- was 5% respectively. The percentage of CAD WDM subjects
with BMI<30 kg/m2 and Grade III -severity- was 16%, Grade II coronary artery disease - was
5% and Grade I -coronary artery disease- was 12% respectively.(Table.7.)
The percentage of CAD WNDM patients with BMI>30 kg/m2 and Grade III-coronary artery
disease - was 20%, Grade II coronary artery disease - was 17% and Grade I -coronary artery
HDL, apo B/apo A1 ratio, Diabetes Mellitus and Cardiovascular Disease
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disease- was 8% respectively. The percentage of CAD WDM subjects with BMI<30 kg/m2 and
Grade III -severity- was 6%, Grade II coronary artery disease - was 11% and Grade I -coronary
artery disease- was 38% respectively.
7. Lipid parameters
7.1. Total cholesterol, triglycerides, HDL-C, LDL-C and VLDL
CAD WDM subjects were 169±3.0, 182.2 ± 8.485 and 197.49 ± 7.77 respectively. The level of
total cholesterol was significantly high in CAD WDM and CAD WNDM) when compared to
control. But no difference was observed between the CAD WDM and CAD WNDM. The
triglyceride level was I21.35±11.28, 131.6 ± 6.4 and 157.5 ± 8.5 in normal controls, CAD WNDM
and CAD WDM subjects respectively.The triglyceride level in CAD WDM was significantly
high (p<0.05) when compared to CAD WNDM. The mean HDL cholesterol level of the normal
controls, CAD WNDM and CAD WDM subjects were 41.48±5.59, 38.4 ± 2.07 and 35.05 ±1.44
respectively.Also the HDL level in CAD WDM was found to be low when compared to normal
controls but was not significant in CAD WDM Vs CAD WNDM. The LDL-cholesterol level
was 104.48±33.5, 129.50 ± 8.8 and 144.25 ± 8.2 respectively in normal controls, CAD WNDM
and CAD WDM subjects. LDL level was significantly(p<0.05) high in CAD WDM when
compared to CAD WNDM and control subjects. The mean VLDL level of the normal controls,
CAD WNDM and CAD WDM subjects were 24.27±2.26, 26.3±13.01 and 31.5 ± 9.617 respec‐
tively.(Table.8.)
PARAMETERS CONTROL(N=71) CAD WDM(N= 52) CAD WNDM(N=57)
Total cholesterol (mg/dL) 169.00±8.00 182.20 ± 8.49a 197.49 ± 7.77a,
Serum Triglycerides (mg/dL) I21.35±11.28 131.60 ± 6.40 157.50 ± 8.50a,b
HDL cholesterol (mg/dL) 41.48±5.59 38.40 ± 2.07a 35.05 ± 1.44a,b
LDL cholesterol (mg/dL) 104.48±33.50 129.50 ± 8.80 a 144.25 ± 8.20a,b
VLDL (mg/dL) 24.27±2.26 26.3± 13.01 31.5 ± 9.62a
ApoA1( g/L ) 1.39±0.31 1.187 ± 0.21 0.873 ± 0.07a,b
ApoB (g/L ) 0.79±0.12 1.64±0.62a 1.66±1.10a,b
ApoB/A1 ratio 0.59±0.17 2.04±0.84 2.069±1.23a
Table 8. Lipid profile and Apolipoproteins of study subjects.
Data are expressed as (mean ± S.D ). Statistical analysis was done by Anova analysis (post hoc
test : Bonferroni ).a: Statistically significant from Control group at p<0.05; b: Statistically
significant from CAD WNDM at p<0.05. HDL-high density lipoprotein; LDL-low density
lipoprotein; VLDL-very low density lipoprotein
Type 2 Diabetes178
Statistical Analysis was done by Chi Square Test
Figure 2. Lipid profile and severity of CAD in non diabetic subjects.
Figure 3. Lipid profile and severity of CAD in Diabetic subjects.
The CAD patients without diabetes and with total cholesterol level <200 mg/dl were 21% with
grade III stenosis, 18% with grade II and 48% with grade I stenosis. The CAD subjects without
diabetes and Total cholesterol level >200 mg/dl had 6% with grade III stenosis, 4% with grade
II and 2% with grade I stenosis. Among the CAD without diabetes subjects with total trigly‐
ceride level <150 mg/dl 13% subjects had grade III stenosis, 6% had grade II and 42% had grade
I stenosis. Compared to 19% subjects with grade III stenosis, 15% with grade II and 4% with
grade I stenosis and triglyceride level >150 mg/dl. The CAD subjects without diabetes and
HDL level <40 mg/dl had 19% with grade III stenosis, 8% with grade II and 33% with grade I
stenosis. The CAD subjects without diabetes and HDL >40 mg/dl had 15% with grade III
stenosis, 10% with grade II and 15% with grade I stenosis. Among the CAD without diabetes
HDL, apo B/apo A1 ratio, Diabetes Mellitus and Cardiovascular Disease
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subjects with LDL level <130 mg/dl 10% subjects had grade III stenosis, 12% had grade II and
23% had grade I stenosis,compared to 21% subjects with grade III stenosis, 10% with grade II
and 23% with grade I stenosis with LDL level >130 mg/dl.
Among the CAD with diabetes subjects with total cholesterol level <200 mg/dl 37% subjects
had grade III stenosis, 7% had grade II and 4% had grade I stenosis. Among the CAD subjects
with >200 mg/dl cholesterol level,4% of subjects had Grade III,7% had grade II and 4% had
grade I stenosis.Among CAD with diabetes and triglyceride level <150 mg/dl 33% had grade
III stenosis, 19% had grade II and 28% had grade I stenosis. Among CAD subjects with
triglyceride level >150 mg/dl were found to have 11% of subjects with grade III,7% with grade
II and 2% with grade I stenosis. Among the CAD with diabetes subjects with total HDL level
<40 mg/dl 30% subjects had grade III stenosis, 18% had grade II and 19% had grade I stenosis.
Among the CAD subjects with 40-60 mg/dl HDL level 12% of subjects had Grade III,11% had
grade II and 11% had grade I stenosis.
The CAD subjects with diabetes and LDL level <130 mg/dl had 25% with grade III stenosis,
18% with grade II and 14% with grade I stenosis. The CAD subjects with diabetes and LDL
level >130 mg/dl had 18% with grade III stenosis, 12% with grade II and 14% with grade I
stenosis.
Lipid parameters IR IN CAD WITH DM
r value p value
T.Cholesterol (mg/dl) -0.211 0.115
Triglyceride (mg/dl) 0.343 0.009**
HDL-C (mg/dl) 0.026 0.847
LDL-C (mg/dl) -0.109 0.12
VLDL (mg/dl) -0.357 0.006**
** significant at p<0.01 and * denoted significant at p<0.001. statistical analysis was done by Pearson correlation.
Table 9. Correlation analysis of Lipid profile with Insulin Resistance
Table.9.depicts the results of the Pearson correlation analysis between different variables in
CAD patients. In CAD with type 2 diabetes population triglyceride showed significant
association with IR (r=..343, p<0.01) and VLDL showed significant correlation with IR.(r=.
357,p<0.01).
In CAD WDM subjects 77% had HDL-C level less than 40 mg/dl when compared to 56% in
CAD WNDM. In CAD WDM 23% had HDL-C level >40mg/dl when compared to 44% in CAD
WNDM.The HDL-C level was found to be not significant between the CAD WDM and CAD
WNDM.
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The CAD subjects were graded into I,II,III based on severity. Statistical analysis was done by
Chi square test.
The distribution of subjects based on HDL cholesterol level <40 mg/dl had shown that 32%
had Grade I stenosis,25% had Grade II stenosis and 16% had Grade III stenosis.. Among the
CAD subjects with HDL level 40-60 mg/dl 19% had grade I stenosis,14% had Grade II stenosis
and 3% had Grade III stenosis.(Fig.4)
The mean ApoA1 level was 1.39±0.31, 1.187 ± 0.205 and 0.873 ± 0.007 in normal controls, CAD
WNDM and CAD WDM subjects.ApoA1was found to be significant with p<0.05 in CAD WDM
CADWDN: Coronary artery disease patients with DM and CAD WNDM : Coronary artery disease patients without type 2
diabetes.. Statistical analysis was done by Anova(post hoc test : Bonferroni).
Table 10. HDL C level in CAD subjects
Figure 4. HDL –C among the CAD subjects based on severity of CAD.
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compared to normal control. ApoB level was 0.79±0.12, 1.64± 0.621and for 1.66 ± 1.10 respec‐
tively in normal controls,
CAD WNDM and CAD WDM subjects. ApoB/A1 ratio in normal subjects in CAD WNDM and
in CAD WDM was 0.59±0.173, 2.04 ± 0.84712 and 2.06 ± 0.84712 respectively. ApoB/A ratio was
found to be significant at p<0.05 in CAD with diabetic subjects when compared to CAD with
no diabetes and normal controls. (Fig.5)
Data are expressed as (mean ± S.D). a: significantly different from control group at p<0.05; b:
significantly different from CAD patients without DM at p<0.05.. Statistical analysis was done
by Anova analysis (post hoc test : Bonferroni)
Cut off values: ApoB/A1 ratio above 1.0 was considered to be at risk. (Benton et al., 2005).
Statistical analysis was done by chi square test.
In CAD WNDM 8% had grade I CAD and ApoB/A ratio less than 1.0 g/L when compared to
4% with grade I CAD in CAD WDM,4% of CAD WNDM had grade II CAD and ApoB/A ratio
less than 1.0 g/L when compared to an equal 4% in CAD WDM. 4%of subjects had CAD WNDM
and grade III when compared to5% in CAD WDM and grade III severity with an ApoB/A1
ratio < 1.0. In CAD WNDM 48%had ApoB/A ratio >1.0 and grade I CAD when compared to
14%in CAD WDM.15% of CAD WNDM had ApoB/A ratio >1.0and grade II CAD when
compared to 28% in CAD WDM.21% of CAD WNDM subjects had ApoB/A ratio >1.0 and
grade III CAD when compared to 49%in CAD WDM. (Fig.6)
Figure 5. ApoA1,ApoB,and ApoB/A ratio in study subjects
Type 2 Diabetes182
Table 11 depicts the results of the Pearson correlation analysis between different variables in
CAD patients.. In CAD with type 2 diabetes population,ApoB/A1 ratio showed negative
correlation with IR (r,-..413, p,0.001).
Statistical analysis was done by Anova analysis (post hoc test : Bonferroni)
The level of Apo A1 was found to be significantly low ( p <0.001) in CAD WDM compared to
CAD WNDM.18% of CAD WDM patients had ApoA1 level >1g/L compared to 38% in CAD
Figure 6. ApoB/Apo A1 ratio and Severity of CAD.
Apolipoproteins IR IN CAD WDM
r value p value
ApoA1( g/L ) .098 -.073
ApoB ( g/L ) .467 .591
ApoB/A1 ratio -.413 .001**
Statistical Analysis was done by Pearson correlation
Table 11. Correlation studies of Apoproteins with Insulin resistance in CAD subjects
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WNDM. 82%of CAD WDM subjects had ApoA1 level <1g/L compared to 62 % in CAD WNDM.
(Table.11)
Correlation analysis between ApoA1 and lipid profile in CAD WDM had shown a significant
positive association with HDL-C (r,.755, p=.000).ApoA1 also showed significant positive
association with HDL-C (r,.415, p=.002) in CAD WNDM.(Table.12)
7.2. Discussion
Age has not been considered to be a modifiable risk factor but, it out-ranks all other factors
like lipids, blood pressure, and smoking—as a predictor of clinical events(Lloyd-Jones et al.,
2004). Conventional analyses do not distinguish between the biological changes of ageing
within arteries—the non-modifiable effects of disintegration of tissues over time—and those
produced by exposure over time to risk factors such as atherogenic dyslipoproteinaemia.
(Lloyd-Jones et al., 2004). The incidence of CAD was high among the patients of the age group
51-60 (77%) in CAD with type 2 DM patients when compared to CAD without DM (46%).
Smoking has been considered as a predictor of the transition from normoglycaemia to impaired
fasting glucose and was found to increase the risk of type 2 diabetes, independent from possible
confounders. Smoking and diabetes are two important hazards to the health of many indi‐
viduals and contribute substantially to the global burden of disease in various ways. Smoking
can not only aggravate the diabetes complications such as macro- or microvascular disease,
but has also been shown to deteriorate glucose metabolism in normal subjects and thereby
may provoke the onset of type 2 diabetes (Robert, Fagard, Nilsson, 2009)
Pathophysiological mechanisms by which smoking causes glucose intolerance and worsens
clinical outcomes in established diabetes include greater insulin resistance, impaired beta-cell
function and insulin secretion, chronic low grade inflammation, endothelial dysfunction, as
well as interacting indirectly with other factors known to aggravate diabetes and lifestyle
factors. (Robert et al., 2009) Table 1. had shown that there was no significant difference between
two groups with respect to smoking, alcoholism and SBP.
According to the percentage of stenosis and involvement of coronary vessels, severity of CAD
was assessed and classified as Grade I(mild), Grade II(Moderate) and Grade III(Severe).
Analysis on frequency of distribution has revealed that severity was significantly high in CAD
WDM. (Table : 4) The percentage of patients with severe coronary artery disease-Grade III was
CAD subjects Apo A1( g/L )
<1.0 >1.0
CAD WN DM 32(62%) 20(38%)
CAD W DM 47(82%) 10(18%)
ApoA1 level of 1.0 g/L. was considered as cut off value
Table 12. Level of ApoA1 in CAD patients
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63% in CAD WDM Vs 25 % in CAD WN DM(p<0.001). 21% of CAD WDM patients had Grade
II (moderate) compared to 29% in CAD WNDM.16% of CAD WDM had Grade I (mild) disease
compared to 46% in CAD WNDM. A significantly high percentage of multivessel atheroscle‐
rosis was observed in CAD WDM when compared to CAD WNDM. These findings showed
a delayed recognition of CAD in type 2 DM. The typical symptoms of cardiac ischemia are
often masked in diabetic patients. Hence the pathological events are not identified at the
preliminary stages (Hanif et al., 2009). This might be the reason for the observed high frequency
of grade III severity in CAD WDM and high percentage of CAD related mortality in diabetic
patients as observed in various epidemiological studies. (Goraya et al., 2002)
8. Insulin resistance
Insulin resistance has been defined as a condition of low insulin sensitivity, in which the ability
of insulin to lower circulating glucose levels is impaired (DeFronzo 2009). The gold standard
for assessing insulin resistance and insulin sensitivity is the hyperinsulinemic euglycemic
clamp technique; however, this test was found to be too labor intensive, time consuming, and
costly for routine clinical practice. The Homeostasis Model Assessment (HOMA) may be used
alternatively as it is minimally invasive, easy to apply in a standard office setting and provide
reasonable indices of insulin action in pre diabetes and diseases of recent onset(Matthews et
al., 1985; Katz A et al., 2000). The biochemical defects that provoke insulin resistance involve
impaired insulin signaling as well as reductions in glucose transport within insulin-sensitive
tissues. (Lewis et al., 2002).So subjects with insulin resistance require more insulin to promote
glucose uptake by peripheral tissues, and genetically predisposed individuals may lack the
necessary beta-cell secretory capacity. Insulin resistance mainly influence the metabolism
related to Liver, Muscle and fat cells. Thus resulting relative insulin insufficiency disrupts the
regulation of glucose production in the liver, glucose uptake in muscle, and the release of fatty
acid from adipose tissue, the outcome being postprandial, and later fasting hyperglycemia.
( Hajer GR et al., 2007)
Analysis on frequency of distribution has revealed that severity was significantly high in CAD
subjects with IR >1.6. (Table 6)The percentage of patients with IR >1.6 and Grade III-coronary
artery disease - was 69%, Grade II coronary artery disease - was 21% and Grade I -coronary
artery disease- was 16% respectively. The percentage of subjects with IR <1.6 and Grade III -
severity- was 8%, Grade II coronary artery disease - was 35% and Grade I -coronary artery
disease- was 30% respectively. Our results have shown that severity was significantly high in
patients with an elevated IR level.(p<0.0001) and coincide with the findings of Bodlaj. (Bodlaj
et al. 2006).
Insulin resistance not only contributes to the pathogenesis of type 2 diabetes but also linked
to cardiovascular risk factors and premature cardiovascular disease. It has been reported that
insulin resistance predisposes individuals to the development of obesity and dyslipidemia
which are considered as the traditional risk factors.
HDL, apo B/apo A1 ratio, Diabetes Mellitus and Cardiovascular Disease
http://dx.doi.org/10.5772/56476
185
As insulin stimulates the production of NO which has both antiatherogenic and anti inflam‐
matory effects, IR is considered as an endothelial dysfunction risk equivalent (Zeng G et al.,
2000;. Kuboki K et al., 2000) IR results in the down regulation of the antiatherogenic phospha‐
tidylinositol-3-kinase–mediated insulin receptor signaling pathway, and maintained activity
of the proatherogenic mitogenic activated protein kinase pathway(Bansilal S et al., 2007). It also
results in a state of low-grade, chronic, systemic inflammation, which in turn links the
metabolic and the vascular pathologies (Romano et al., 2003; Hsueh and Law,2003; Haffner
SM.,2003) All these might have lead to accelerated atherosclerosis and increased severity of
CAD in patients with type 2 DM.
9. Body Mass Index (BMI)
Body mass index (BMI) is a simple index of weight-for-height that is commonly used to classify
overweight and obesity in adults. The WHO defines a BMI greater than or equal to 25 is
overweight and a BMI greater than or equal to 30 is obesity(World Health Organization,
2007).BMI provides the most useful population-level measure of overweight and obesity as it
is the same for both sexes and for all ages of adults. Raised BMI is a major risk factor for non-
communicable diseases such as CAD (Niraj et al.2007) In our study significantly high level of
BMI was observed in the CAD WDM subjects when compared to CAD WNDM and control
(with p<0.001).The mean BMI level was 32.05 ± 0.33 in CAD WDM, 27.82 ± 3.359 in CAD
WNDM and 20.05±0.95 in the control group respectively (Table.7.). Abbasi et al had shown
similar results in their studies. (Abbasi et al., 2002).
This increase in BMI might be due to the Insulin resistance, the major causative factor for type
2 DM. (Goossens, 2008) IR greatly reduces the sensitivity of cell walls to insulin. So the vital
Figure 7. Obesity and IR related to hyperglycemia
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process whereby glucose passes through the cell wall via insulin to be converted into energy
gets greatly impaired.
As a result, excess glucose remains in the blood stream, causing elevated levels of blood sugar,
which are sent to the liver. (Niraj et al/ 2007) Once it reaches there, the sugar gets converted
into fat and carried via the blood stream throughout the body. This process can lead to weight
gain and obesity.
Evidences have revealed that normal function of Adipose issue is disturbed during obesity
and adipose tissue dysfunction plays a prominent role in the development and/or progression
of insulin resistance (Goossens.,2008). Boden and Chen et al had identified that Insulin-
resistant fat cells of obesity can confer insulin resistance to muscle through the excessive release
of free fatty acids into the general circulation and/or through the accumulation of intra
myocellular triglyceride (Boden, 1997 and Chen et al., 1988). Since obesity has been recognized
as a significant contributor to hypertension, dyslipidemia and Insulin resistance, it has been
recognized as a major modifiable risk factor for cardiovascular disease (Sharma,2003). This
might be the reason for the observed significantly high percentage of incidence of CAD and
severity in CAD patients with BMI >30 kg/m2.
The  athero-thrombotic  process  that  underlies  CVD implies  a  central  role  for  cholesterol
metabolism. The average concentration of blood cholesterol within a population has been
found to be an important determinant of the risk of CHD in the population (Corti Salive
et  al.,  1997).  Girard,  had found that  high cholesterol  levels  augments the risk of  several
diseases, most notably cardiovascular diseases( Girard-Mauduit,2010). In the present study
cholesterol  level  was found to be significantly high in CAD patients when compared to
control subjects. As its concentration increases, Cholesterol-rich apoproteins B containing
lipoproteins may infiltrate the subendothelial space and initiate an inflammatory process
that leads to atherosclerotic lesions. This progresses to fibrous plaques, with necrotic scores.
(Paik.and Blair.,1995). Abnormal concentration of cholesterol also increase platelet aggrega‐
tion,  which  exacerbates  the  severity  of  athero-thrombotic  process.  Hence  cholesterol
metabolism occupies a central role in the pathophysiology of CVD and found to be high
in CAD patients (Enas,yousuf, Mehta, 1992).
In the present study total cholesterol level in CAD patients does not show any significant
change with severity of CAD which underlines the fact that blood cholesterol alone may be a
relatively poor predictor for CHD. (Table 9) This might be due to the fact that the other major
risk factors might have exerted a component of their adverse effects via their effects on the
above mentioned aspects of cholesterol metabolism. (David.,2001)
In the study, plasma triglyceride and VLDL were found to be significantly high in CAD WDM
when compared to control and CAD WNDM.(Table 9) Hypertriglyceridemia has been found
to be one of the most consistent finding in type 2 diabetes patients (Saxena et al., 2005).
Evidence from both animal and human studies implied that insulin resistance which causes
increased synthesis and/or decreased clearance of VLDL – has been an important underlying
cause of hypertriglyceridemia in subjects with type 2DM (Hopkinns et al.2009).
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Insulin an anabolic hormone was found to play a central role in the lipid synthesis and
inhibition of lipolysis. Insulin inhibit VLDL production from the liver indirectly by decreasing
FFA flux from adipose tissue to the liver and directly by its inhibitory effect on the rate of ApoB
100 synthesis and degradation in hepatocytes It has also been identified that Insulin can inhibit
the assembly and secretion of VLDL by increasing posttranslational degradation of ApoB and
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reducing the expression of MTP (microsomal triglyceride transfer protein) in the liver(Mesh‐
kani and Adeli 2009).
One of the major abnormalities in insulin resistance was found to be hepatic overproduction
of VLDL(Meyer et al., 1996). It influences hepatic VLDL production by increasing the free fatty
acid flux to liver and by affecting the rate of ApoB synthesis. It also reduces VLDL and
intermediate density lipoprotein(IDL) catabolism by reducing the activity of lipoprotein lipase
and decrease the hepatic uptake of VLDL and IDL. (Miller M;1999) These could have been the
reason behind the significantly high level of TG and VLDL in CAD with diabetes subjects.
(Figure 2 and 3)
Triglyceride was widely accepted as a CAD risk factor synergistic with other lipid risk factors.
Helsinki Heart Study and 6-year follow-up of the observational Prospective Cardiovascular
Muenster (PROCAM) study, revealed the importance of triglyceride as major risk factor.
(Antonio Jr, 1998) Gianturco et al., had shown that macrophages may take up triglyceride-rich
lipoproteins by a mechanism that was independent of the ApoB/E receptor, there by facilitating
the formation of atherogenic foam cells. (Gianturco et al., 1994) Hypertriglyceridemia was
found to have some adverse effect on endothelial dysfunction and activation on coagula‐
tion.These involvement of hyper triglyceridemia in atherogenesis at various level could have
resulted in positive correlation of TG level with severity of CAD. (Table 9).
10. Low density lipoprotein — C
The concentration of serum LDL was found to be directly related to the development of
atherosclerosis. One current theory which relates the role of LDL in the institution of athero‐
sclerosis propose that oxidized LDL plays a major role in the development of foam cell-laden
fatty streaks in the arterial wall. Elevated low-density lipoprotein cholesterol (LDL-C) has been
a well-established independent risk factor for coronary artery disease (CAD). A number of
primary and secondary trials have demonstrated that lowering of LDL-C decreases the
incidence of CAD.
The present study has shown that LDL level was significantly elevated in CAD with diabetes
subjects when compared to the CAD without diabetic group and normal controls. Reports
have revealed that T2D patients show decreased hepatic uptake of VLDL, IDL and LDL that
lead to increased plasma levels of these lipoproteins particularly in the postprandial state. This
condition is observed particularly when there is marked insulin deficiency or poor glycemic
control in type T2D (Lewis et al., 2002). It has also been reported that clearance of LDL was
limited due to the decreased availability of LDL receptors. So the high insulin resistance
reported in CAD WDM might be the etiology behind the observed high level of LDL.
Patients with type 2 diabetes frequently have normal or only slightly elevated LDL-cholesterol
concentrations but increased numbers of atherogenic LDL particles owing to the predomi‐
nance of small, dense LDL particles. The basis for formation of sdLDL in insulin resistant states
relates to the action of two proteins; cholesteryl ester transfer protein (CETP) and hepatic
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lipase. CETP mediates the exchange of VLDL triglyceride for LDL cholesteryl ester, creating
a triglyceride-enriched, cholesterol depleted LDL particle. This LDL particle is a substrate for
hepatic lipase leading to hydrolysis of triglyceride and formation of the sdLDL (Olofsson et
al., 2005) Increased CETP and hepatic lipase activity, observed in insulin resistant and type
2diabetes subjects, favor the formation of sdLDL (Bagdade et al., 1993 and Riemens et al., 1998)A
predominance of small, dense LDL particles is associated with increased risk of CHD (Austin
et al., 1988, Gardner et al., 1996).These particles are more powerful than larger LDL particles
to penetrate the vessel intimal wall and are more exposed to oxidation; oxidized LDL are then
taken up by macrophages as part of atherosclerotic plaque formation. Small, dense LDL is also
associated with early vascular dysfunction in the form of impaired endothelial response in
patients with diabetes independent of other risk factor variables, including lipid levels, body
mass index (BMI), blood pressure and severity. ( Tan et al., 1999).
Hence the absolute LDL-cholesterol concentration could be misleading, since it does not
directly reflect the increased number of atherogenic particles. This might have led to the lack
of positive correlation between LDL cholesterol with Insulin resistance and severity of CAD.
(Tan et al., 1999).
The CAD patients without diabetes and with total cholesterol level <200 mg/dl were 21% with
grade III stenosis, 18% with grade II and 48% with grade I stenosis. The CAD subjects without
diabetes and Total cholesterol level >200 mg/dl had 6% with grade III stenosis, 4% with grade
II and 2% with grade I stenosis. Among the CAD without diabetes subjects with total trigly‐
ceride level <150 mg/dl 13% subjects had grade III stenosis, 6% had grade II and 42% had grade
I stenosis. Compared to 19% subjects with grade III stenosis, 15% with grade II and 4% with
grade I stenosis and triglyceride level >150 mg/dl. The CAD subjects without diabetes and
HDL level <40 mg/dl had 19% with grade III stenosis, 8% with grade II and 33% with grade I
stenosis.
The CAD subjects without diabetes and HDL >40 mg/dl had 15% with grade III stenosis, 10%
with grade II and 15% with grade I stenosis. Among the CAD without diabetes subjects with
LDL level <130 mg/dl 10% subjects had grade III stenosis, 12% had grade II and 23% had grade
I stenosis,compared to 21% subjects with grade III stenosis, 10% with grade II and 23% with
grade I stenosis with LDL level >130 mg/dl.
Among the CAD with diabetes subjects with total cholesterol level <200 mg/dl 37% subjects
had grade III stenosis, 7% had grade II and 4% had grade I stenosis. Among the CAD subjects
with >200 mg/dl cholesterol level,4% of subjects had Grade III,7% had grade II and 4% had
grade I stenosis.Among CAD with diabetes and triglyceride level <150 mg/dl 33% had grade
III stenosis, 19% had grade II and 28% had grade I stenosis. Among CAD subjects with
triglyceride level >150 mg/dl were found to have 11% of subjects with grade III,7% with grade
II and 2% with grade I stenosis. Among the CAD with diabetes subjects with total HDL level
<40 mg/dl 30% subjects had grade III stenosis, 18% had grade II and 19% had grade I stenosis.
Among the CAD subjects with 40-60 mg/dl HDL level 12% of subjects had Grade III,11% had
grade II and 11% had grade I stenosis.
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The CAD subjects with diabetes and LDL level <130 mg/dl had 25% with grade III stenosis,
18% with grade II and 14% with grade I stenosis. The CAD subjects with diabetes and LDL
level >130 mg/dl had 18% with grade III stenosis, 12% with grade II and 14% with grade I
stenosis.
The distribution of subjects based on HDL cholesterol level <40 mg/dl had shown that 32%
had Grade I stenosis,25% had Grade II stenosis and 16% had Grade III stenosis.. Among the
CAD subjects with HDL level 40-60 mg/dl 19% had grade I stenosis,14% had Grade II stenosis
and 3% had Grade III stenosis.
HDL-C has been considered as an antiatherogenic lipid factor as it helps in reverse cholesterol
transport (Hersberger et.al.,2005). Furthermore HDL particles have been shown to have
cardioprotective nature due to its - antioxidant properties, protective effect on endothelial cells,
inhibitory effect on endothelial adhesion and activation of leukocytes, inhibitory action on
platelet activation (Nofer et al., 2002). In our study, HDL-C level has been found to be signifi‐
cantly lowered in CAD patients when compared to normal. These results draw a parallel with
the existing reports (Grundy,et.al., 2004). Reduced HDL levels have been commonly observed
in metabolic syndrome and type 2 diabetes subjects. The reduced HDL cholesterol levels found
in CAD WDM may be due to the high Apo E-containing triglyceride-rich lipoproteins found
in these patients. Apo E is involved in HDL catabolism and can transfer from triglyceride-rich
lipoproteins to HDL. Furthermore, when present on HDL particles, apo E is predominantly
associated with LpAI/AII (Lipoprotein lipase AI/AII) particles. Therefore, the elevation of
circulating apo E-containing triglyceride- rich lipoproteins could lead to increased transfer of
apo E to LpAI/AII (Lipoprotein AI/AII) and enhanced catabolism of this fraction. (Juying Ji et
al., 2006)
Functions and properties of HDL particle vary according to its particle size and apoproteins
content. It exists as particles of different sizes, with HDL- 2 being the largest and containing
the most lipid in its core. HDL-3 particles are smaller and pre-b-HDL is the smallest, and these
may be the most active particles in taking up peripheral cholesterol (Benton et al., 2005).
Apolipoprotein composition can be used to separate HDL into subpopulations: HDL contain‐
ing apo A-I and apo A-II (HDL A-I : A-II), and HDL containing apo A-I but not apo A-II (HDL
A-I)( Kuller et al., 2002). HDL A-I is more effective than HDL A-I : A-II in promoting cholesterol
efflux ( Kuller et al., 2002), which is consistent with the atheroprotective effect of apo A-I on
LCAT (Walldius et al., 2001 and Sharet et al., 1994). The Prospective Epidemiological Study of
Myocardial Infarction (PRIME) study examined the association between the incidence of CHD
and several HDL related parameters, including HDL-C itself, apo A-I, HDL A-I, and HDL A-
I : A-II (Ensign et al., 2006). All four parameters were related to CHD risk, however, HDL apo
A-I, and apo A-I were the strongest predictor. This might be the reason why HDL had no
positive correlation with severity of CAD in the present study.
10.1. Apolipoprotein A1
An  inverse  relationship  between  the  concentration  of  high-density  lipoprotein  (HDL)
cholesterol and the risk of developing cardiovascular is well established. There are several
documented functions  of  HDLs that  may contribute  to  a  protective  role  of  the  lipopro‐
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teins. These include the ability of HDLs to promote the efflux of cholesterol from macro‐
phages and foam cells in the artery wall and to anti inflammatory/antioxidant properties
of  these lipoproteins.  (Gotto AM J  et  al.,  1983)  The fact  that  the main apolipoprotein of
HDLs, ApoA-I, plays a prominent role in each of these functions adds support to the view
that ApoA-I should be measured as a component of the assessment of cardiovascular risk
in  humans  (Robinson  D  et  al.,  1987).  Moreover  there  is  mounting  evidence  that  HDL
subpopulations vary in terms of their ability to protect against CHD. Case-control studies
have suggested that the inverse relationship between HDL cholesterol concentration and
CHD is  a  function of  the  concentration of  the  HDL subfractions  (Miller  et  al.,  1987).  In
another study relating HDL subpopulations to CHD, it was found that both the severity
and the rate of progression of coronary lesions correlate significantly and inversely with
the concentration of types of HDL( Stamper et al., 1991).
Level  of  Apolipoproteins  overwhelms the  lipids  because  ApoA1are  under  more  genetic
control than lipid components and hence depicts the number of lipoprotein particles more
accurately (Walldius G and I Jungner I, 2006) The present study has shown that the level
of Apo A1 was significantly low in CAD with diabetic subjects when compared to CAD
without diabetes. This might be due to the presence of high level of Apo E which cause
the catabolism of Apo A1 and HDL.
APO-A1 is the major structural protein of HDL(70%)and it has major role is centripetal
movement of cholesterol from peripheral tissues including the arterial wall to the liver for
eventual elimination of through the biliary system in to the gut.(Sniderman A D et al., 2003 )The
transport of cholesterol and formation of HDL are the basic roles of APO-A1.,low levels of this
proteins have been identified as the risk factor in the development and progression of coronary
damage. (Sniderman A D et al., 1997). Apo A1 not only initiates the reverse cholesterol
transport by activating the LCAT but also manifests antioxidant and antiinflammatory effects
(Walldius G and Jungner I.,2004) It also removes oxidative seeding molecules from endothe‐
lium, Scavenges toxic products from arterial wall, ’Reduces smooth muscle cell, apoptosis/
necrosis’, Reduces plaque lipid content, Reduces plaque macrophage content and Improves
endothelial dysfunction. Furthermore, apo A-I is the ligand for the ATP-binding cassette (ABC)
protein, ABCA1,and hence is involved in the docking procedure by which excess cholesterol
in peripheral cells is externalized to HDL (Oram et al., 2000 and Wang N et al., 2001) for further
reverse cholesterol transport either directly or indirectly via LDL back to the liver Hence it can
be considered as a better marker than HDL-C (Oram et al., 2000).
10.2. Apolipoprotein B(apoB)
For over three decades it has been recognized that a high level of total blood cholesterol,
particularly in the form of LDL cholesterol (LDL-C), is a major risk factor for developing
coronary heart disease (CHD) ( Walldius G and Jungner I.,2001)However, recent research has
shown that LDL-C is not the only lipoprotein species involved in atherogenesis. Elevated levels
of intermediate- density lipoprotein (IDL) and very low density lipoprotein (VLDL) are also
associated with increased cardiovascular risk. All these potentially atherogenic lipoprotein
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contain one Apo B molecule.and therefore the total apo B value indicates the total number of
potentially atherogenic lipoproteins (Scharnagl H et al., 2001 and Nissen et al. 2003)
In our study Apo B was found to be significantly high in CAD with type 2 DM when compared
to CAD without DM and control subjects. This observation coincide with the findings several
studies related to coronary heart disease
Apo B is essential for the binding of LDL particles to the LDL receptor, allowing cells to
internalize LDL and thus absorb cholesterol (Alfonso Troisia,, Alberto D’Argeniob,2006). The
concentration of plasma apo B particles is highly correlated with the level of non-HDL
cholesterol (non-HDL-C), defined as TC minus HDL-C ( Chapman and Caslek, 2004) As HDL
is known to be protective against cardiovascular risk, non-HDL-C reflects the fraction of blood
cholesterol that is not contained in atheroprotective lipoproteins. Thus apo B has been found
to be a better predictor of risk than LDL-c, VLDL and chylomicrons. In most conditions, more
than 90% of all ApoB in blood is found in LDL. In some cases where LDL C is in the
normal/low range, high ApoB levels were observed which indicate an increased number of
sd-LDL particles, - most atherogenic particles as they are easily oxidized and promote an
inflammatory response and the growth of plaques. Furthermore Apo B has been found to be
an independent predictor of endothelial vasodilatory function, increased carotid IMT and
arterial stiffness. These properties and the observation from the present study that Apo B is
positively correlated to the severity of the CAD underline the simple fact that an excess of apo
B- particles always denote proatherogenic condition.
10.3. ApoB/A ratio
An early detection of the people at high risk for CAD can reverse or reduce the worsening of
condition by modification of lifestyle of patient, an establishment of robust and precise risk
indicator for lipid imbalance and atherogenesis will be of great practical advantage for patients
and physicians. (Nam BH, 2006 ).
LDL-C had been considered as the major atherogenic lipoprotein particles for many years and
the prime predictor for CAD (Vogel RA, 1998).Now it has been identified that Apolipoprotein
B represent total atherogenic particles and is better predictor than other lipoproteins. ( Wall‐
dius G, Jungner I.,2004). ApoA-I the major apolipoprotein in HDL particles has a central role
in the ‘reverse cholesterol transport’and manifests anti-inflammatory and antioxidant effects.
It has been identified that Apo A1 can be risk factor than HDL cholesterol and can be considered
as for antiatherogenic marker. (Walldius G and Jungner I. 2004).
So to get a precise picture of both atherogenic and antiatherogenic lipid related risk, ratio of
ApoB/ApoA1 was considered. The ratio between the concentrations of ApoB and ApoAI
(henceforth ApoB/A) reflect the balance between the opposing processes of arterial internali‐
zation of cholesterol and the reverse transport of cholesterol back to the liver (Walldius G and
Jungner I.,2005). The reason for improved predictive effect of ApoB/A ratio might be due to
the fact that the ratio reflects and integrates the “ cholesterol balance “ between potentially
atherogenic lipoprotein particles (ApoB) in relation to all antiatherogenic particles.(ApoA1).
It has been found to be better than one single lipid fraction or the LDL-C/HDL-C ratio. Another
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contributing explanation is that the methodological errors of the apolipoprteins are smaller
than those for lipids. (Walldius G and Jungner I, 2005).
In the present study the ApoB/A ratio was found to be markedly elevated ( p≤ 0.001)in CAD
patients irrespective of their Diabetes status. The ApoB/A ratio and severity of CAD was not
found to be significant in CAD WNDM (r=1.000,p =.809) whereas the ratio and severity was
significant(p<.05) in CAD WDM with(r=.547 p =.034.The risk relationship between ApoB and
ApoA1 was expressed as Odds ratio. The Odds ratio for CAD WNDM was 0.48 while Odds
ratio for CAD WDM was found to be 4.5 (95% CI: 1.122 - 18.31).(Table.8-10)
The ratio reflects the balance of cholesterol transport and can be expressed as one number
which integrates the risk associated with an imbalance between atherogenic and antiathero‐
genic lipoproteins. The strongest single variable in AMORIS, related to increased risk of fatal
MI, was the ApoB/ApoA-I ratio. AMORIS study showed that the ratio of ApoB /A1 can indicate
the risk of MI irrespective of lipid phenotype and even if lipid levels are normal/low.(van
Lennep et al., 2008) This ratio had a stronger relationship with CV risk than any other lipid
ratio such as total cholesterol (TC)/HDL-C, LDL-C/HDL-C, or non-HDL-C/HDL-C. Talmud et
al have confirmed the results from the AMORIS study and found that the ratio was a better
predictor of cardiac risk than LDL-C, and that both apo B with TG and found to have the
strongest associations with CHD. ( Talmud PJ et al., 2002)
Epidemiologic studies indicated that the ratio of ApoB to ApoA-I was the strongest predictor
of CAD (Barter etal.,2006). Similarly, van Lennep et al. (van Lennep et al., 2000) reported in
patients with CAD on statin therapy that only ApoB and the ApoB/ApoA-I ratio predicted
myocardial infarction and all-cause mortality, whereas LDL-C and TG did not. In both men
and women from the AMORIS (Apolipoprotein-Related Mortality Risk) study, the superiority
of the ratio of ApoB to ApoA-I, compared with the TC/HDL-C ratio, became more obvious as
risk of CAD increased.
Our study had shown that instead of still remaining with the old paradigm:’LDL cholesterol-
the lower the better, a new paradigm ApoB/A1 ratio indicating the cholesterol balance –the
lower the better ‘might be more appropriate.
11. Conclusion
Type 2 diabetes mellitus is associated with a three to fourfold increase in risk for coronary
artery disease (CHD). (Diabetes mellitus is associated with sharp increased risk of CVD and
mortality). People with type 2 DM develop CVD at a younger age, have a high rate of multi‐
vessel disease. The typical symptoms of cardiac ischemia are often masked in diabetic patients
Hence the pathological events are not identified at the preliminary stages. Despite advances
in our knowledge, the established risk factors could not fully explain its occurrence: and cannot
be explained by conventional risk factors which lead to delayed recognition of CAD in type 2
DM. Mechanism underlying the accelerated atherosclerosis in DM patients are not fully
understood. Insulin resistance which is the major etiological factor of T2DM influence (affect)
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HDL,LDL and TG level- which can increase the risk of CAD. ApoB/ApoA1 ratio which reflects
both atherogenic and antiatherogenic lipid related risk, can be used as a better predictor than
traditional lipid markers like LDL and HDL to analyze the atherogenicity.
12. Future implications
It is now reported that HDL can influence glucose metabolism directly and possibly im‐
prove  insulin  resistance  by  altering  plasma  membrane  composition  through  enhanced
cholesterol efflux. Balancing cholesterol efflux and influx HDL can promote insulin sensi‐
tivity  enhancing  or  activating  insulin  receptor  function,  its  tyrosine  kinase  activity  and
downstream regulation  of  cellular  function.  It  is  reported  that  glycation  of  certain  resi‐
dues of apo A1 could inhibit its anti-oxidant activity converting HDL into a dysfunctional
molecule which may affect its protective properties including its newly emerging role in
insulin action and glucose metabolism.
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